Letters to the Editor
Tolerance and Dependence Risk with the Use of Carisoprodol
Am Fam Physician. 2004 Apr 1;69(7):1622-1623.
to the editor: Carisoprodol (Soma) is an unscheduled muscle relaxant commonly used in primary care. [corrected] It is metabolized to meprobamate, a schedule IV drug that has a long history of abuse and exhibits cross-tolerance to barbiturates. A small but growing amount of literature is available regarding morbidity associated with the use of carisoprodol, including respiratory compromise1 and vehicle crashes.2 This case report highlights this potential danger.
A 45-year-old man with grand mal seizure disorder, opiate dependence, major depressive disorder, and chronic neck and back pain presented with new-onset nocturnal “blackouts.” He had no history of barbiturate abuse. He described at least three episodes during the past two weeks in which he was found wandering in his neighborhood naked. He had no memory of these events, and could only relate them based on the reports of his neighbors. Although admitting to ongoing intravenous heroin use, there was no apparent temporal link between heroin and these events. He denied recent use of alcohol or other drugs, symptoms of aura or a postictal state, recent head injury or illness, or overuse of his prescribed medications.
His medications at admission and for at least the previous month were: carisoprodol, 700 mg three times daily; gabapentin (Neurontin), 600 mg three times daily; quetiapine (Seroquel), 25 mg every night; zolpidem (Ambien), 10 mg every night; sertraline (Zoloft), 200 mg every night; and ibuprofen, 800 mg three times daily.
Physical examination showed his vital signs were within normal limits. He was alert, oriented, and scored 30 out of 30 on the Mini-Mental State Examination. Urine was only positive for opiates (routine urine drug screens do not detect meprobamate). Electrolytes, liver function tests, complete blood count, vitamin B12, folate, and thyroid-stimulating hormone levels were within normal limits. An electroencephalogram and a non-contrast head computed tomographic scan were unremarkable.
We suspected that he was experiencing amnestic periods secondary to his use of multiple psychoactive medications. Rather than discontinue carisoprodol abruptly, particularly given his seizure disorder, a pentobarbital challenge test was performed to assess his tolerance level to carisoprodol. The pentobarbital challenge test3 involves administration of a test 200 mg dose of pentobarbital and assessment of the patient one hour later for one of four stages of barbiturate tolerance. The patient showed no symptoms of intoxication, indicating that he was at the highest stage of tolerance and, therefore, at risk of delirium, seizures, or even death with abrupt cariso-prodol cessation.4 He was placed on a one-week phenobarbital taper and was both seizure-free and without amnestic episodes during his two-week stay. He left the hospital receiving baclofen (Lioresal), 5 mg three times daily, for his back spasms; carisoprodol, gabapentin, zolpidem, and quetiapine were successfully discontinued.
This case report demonstrates clear barbiturate tolerance caused by the use of carisoprodol. The tolerance and dependence liability of carisoprodol can put patients at risk of severe withdrawal symptoms, including seizures and death. It is a curious inconsistency that carisoprodol is not scheduled, but meprobamate is schedule IV.
1. Davis GG, Alexander CB. A review of carisoprodol deaths in Jefferson County, Alabama. South Med J. 1998;91:726–30.
2. Logan BK, Case GA, Gordon AM. Carisoprodol, meprobamate, and driving impairment. J Forensic Sci. 2000;45:619–23.
3. Bauer MS. Field guide to psychiatric assessment and treatment. Philadelphia, Pa.: Lippincott Williams & Wilkins, 2003.
4. Littrell RA, Hayes LR, Stillner V. Carisoprodol (Soma): a new and cautious perspective on an old agent. South Med J. 1993;86:753–6.
Send letters to Kenneth W. Lin, MD, MPH, Associate Deputy Editor for AFP Online, e-mail: email@example.com, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680.
Please include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.
Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the American Academy of Family Physicians permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.
Copyright © 2004 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions